Mr. Alex Vasilkevich reports

BRIGHT MINDS BIOSCIENCES PROPRIETARY COMPOUND, BMB-201, 5-HT2C/2A MIXED AGONIST, DEMONSTRATED SIMILAR EFFICACY TO MORPHINE IN PRECLINICAL PAIN MODELS

Bright Minds Biosciences Inc. has received positive data from the preclinical testing of BMB-201 completed with the National Institute of Health pain screening program.

Preclinical pain models included plantar incision and L5/L6 nerve ligation rat models, where the drug candidate was tested along with morphine and gabapentin as positive controls.

Key highlights from the study

In nerve ligation pain models, BMB-201 had similar efficacy to morphine, demonstrating superior reductions in mechanical allodynia and pain-related behaviours.

Female rodents experienced a marked improvement in both pain relief and guarding behaviour, with higher doses producing a significant therapeutic effect.

BMB-201's efficacy suggests that it may provide better pain relief than traditional opioid treatments, without the associated risks of dependency and side effects.

"These findings are a significant step forward in our mission to develop safer and more effective treatments for chronic pain," said Jan Torleif Pedersen, chief scientific officer of Bright Minds. "The fact that BMB-201 outperforms morphine in preclinical models is a testament to the potential of serotonergic therapies in pain management."

Next steps: With these promising preclinical results, Bright Minds plans to advance BMB-201 into clinical trials to further evaluate its safety and efficacy in human subjects. The company aims to position BMB-201 as a non-opioid alternative for neuropathic pain relief, addressing a significant unmet need in the pain management landscape. BMB-201 constitutes a novel MoA for the modulation of pain perception.

These data have been presented at Society for Neuroscience's annual meeting at the NIH Satellite Forum.

About BMB-201

BMB-201, a selective 5-HT2A/2C receptor agonist, was designed to harness the analgesic potential of serotonin modulation without the hallucinogenic effects commonly associated with 5-HT2A activation. As a pro-drug of BMB-A39a, it exhibits minimal activity at the 5-HT2B receptor, ensuring a reduced risk of side effects.

About Bright Minds Biosciences Inc.

Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Its pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.

Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

We seek Safe Harbor.